期刊
LIFE-BASEL
卷 11, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/life11121390
关键词
marine drugs; sea pharmaceuticals; EMA; FDA; clinical trials
The Blue Growth policy in European and non-European countries has boosted the research of new bioactive molecules in marine organisms, leading to the development of marine drugs with unique properties that are being used in the treatment of various diseases such as cancer and Alzheimer's.
In the last decades Blue Growth policy in european and non-european countries produced a great impulse in applied marine sciences, comprehending the research of new bioactive molecules in marine organisms. These organisms are a great source of natural compounds with unique features resulting from the huge variability of marine habitats and species living in them. Most of the marine compounds in use and in clinical trials are drugs for cancer therapy and many of them are conjugated to antibody to form antibody-drug conjugates (ADCs). Severe pain, viral infections, hypertriglyceridemia, obesity, Alzheimer's and other CNS diseases are further target conditions for these pharmaceuticals. This review summarizes the state-of-the-art marine drugs focusing on the most successful results in the fast expanding field of marine pharmacology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据